Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis

Abstract

The insulin receptor substrate (IRS) proteins are adaptor molecules that integrate signals generated by receptors that are implicated in human breast cancer. We investigated the specific contribution of IRS-2 to mammary tumor progression using transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary gland and IRS-2-null (IRS-2^−/−) mice. PyV-MT-induced tumor initiation and growth were similar in wild-type (WT) and IRS-2^−/− mice. However, the latency and incidence of metastasis were significantly decreased in the absence of IRS-2 expression. The contribution of IRS-2 to metastasis is intrinsic to the tumor cells, because IRS-2^−/− mammary tumor cells did not metastasize when grown orthotopically in the mammary fat pads of WT mice. WT and IRS-2^−/− tumors contained similar numbers of mitotic cells, but IRS-2^−/− tumors had a higher incidence of apoptosis than did WT tumors. In vitro, IRS-2^−/− mammary tumor cells were less invasive and more apoptotic in response to growth factor deprivation than their WT counterparts. In contrast, IRS-1^−/− tumor cells, which express only IRS-2, were highly invasive and were resistant to apoptotic stimuli. Collectively, our findings reveal an important contribution of IRS-2 to breast cancer metastasis.

We thank Olivier Kocher for his help with analysis of the tumor pathology.

This work was supported by NIH grants CA90583 (L.M.S.) and DK38712 (M.F.W).